MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.46−0.28 (-3.20%)
Close on Nov 17, 2026Market cap $812.52MP/E 11.9Yield –
MeiraGTx total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
MeiraGTx's total debt was $100.00M at Jun 30, 2026. For fiscal 2025 it was $49.69M, down 32.1% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.69M | -32.1% |
| FY2024 | Dec 31, 2024 | $73.22M | +1.5% |
| FY2023 | Dec 31, 2023 | $72.12M | +1.5% |
| FY2022 | Dec 31, 2022 | $71.03M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $100.00M | +36.1% |
| Q1 FY2026 | Mar 31, 2026 | $49.70M | -32.1% |
| Q4 FY2025 | Dec 31, 2025 | $49.69M | -31.9% |
| Q2 FY2025 | Jun 30, 2025 | $73.77M | +1.5% |
| Q1 FY2025 | Mar 31, 2025 | $73.50M | +1.5% |
| Q4 FY2024 | Dec 31, 2024 | $73.22M | +1.5% |
| Q3 FY2024 | Sep 30, 2024 | $72.94M | +1.5% |
| Q2 FY2024 | Jun 30, 2024 | $72.67M | +1.5% |
| Q1 FY2024 | Mar 31, 2024 | $72.39M | +1.5% |
| Q4 FY2023 | Dec 31, 2023 | $72.12M | +1.5% |
| Q3 FY2023 | Sep 30, 2023 | $71.84M | +1.4% |
| Q2 FY2023 | Jun 30, 2023 | $71.57M | – |
| Q1 FY2023 | Mar 31, 2023 | $71.30M | – |
| Q4 FY2022 | Dec 31, 2022 | $71.03M | – |
| Q3 FY2022 | Sep 30, 2022 | $70.85M | – |
See a number that looks wrong?